Updates on analysis of Enzyplex tablet announced
************************************************
During the DH's investigation into a case of suspected mould contamination of the above product, samples of the product were collected from various sources for analysis on June 21 to ascertain whether the product exceeds the pharmacopoeial standards on mould and yeast content.
According to the analysis results available today, the mould and yeast content of all samples comply with both the pharmacopoeial requirements and the in-house specifications set by the Indonesian manufacturer of the product.
However, the DH has announced earlier results of another test which revealed that the bacterial contents of the samples exceeded the in-house specifications even though they passed the pharmacopoeial standards. The local supplier of the product, Unam Corporation Ltd, has recalled all batches of Enzyplex tablet from the market on June 26. The DH has also instructed Unam to ask the manufacturer to conduct an investigation and submit an investigation report as soon as possible.
Unam has set up a hotline (3665 2000) to answer related enquires. So far, the DH has not received any adverse drug reaction reports in connection with the product.
People who have purchased the product should stop taking it. They should also seek advice from healthcare professionals if in doubt or feeling unwell after consumption.
Ends/Thursday, June 28, 2018
Issued at HKT 18:43
Issued at HKT 18:43
NNNN